. C% p. f4 C( _. O) M
临床上有依维莫司联合EGFR TKI作为易/特耐药之后的方案的研究: & o5 ?( t: g' A; ]! b: tEverolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.' i' ^8 k2 N; n, U http://www.ncbi.nlm.nih.gov/pubmed/22968184: I0 Q/ ^$ o2 t1 V. b9 t3 c% R' C
( ^4 I& C C- U3 |6 t/ a: I2 b
依维莫司联合吉非替尼抑制非小细胞肺癌细胞系的效果和作用机制 7 T, D8 O+ Z3 P' R* \http://d.wanfangdata.com.cn/Thesis_Y1770447.aspx